Cargando…
Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors
Management of residual or recurrent disease following thermal ablation of renal cortical tumors includes surveillance, repeat ablation, or surgical extirpation. We present a multicenter experience with regard to the management of this clinical scenario. Prospectively maintained databases were review...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Codon Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331942/ https://www.ncbi.nlm.nih.gov/pubmed/32665886 http://dx.doi.org/10.15586/jkcvhl.2020.133 |
_version_ | 1783553428224475136 |
---|---|
author | Loloi, Justin Shingleton, W. Bruce Nakada, Stephen Y. Zagoria, Ronald J. Landman, Jaime Lee, Benjamin R. Matin, Surena F. Ahrar, Kamran Leveillee, Raymond J. Cadeddu, Jeffrey A. Raman, Jay D. |
author_facet | Loloi, Justin Shingleton, W. Bruce Nakada, Stephen Y. Zagoria, Ronald J. Landman, Jaime Lee, Benjamin R. Matin, Surena F. Ahrar, Kamran Leveillee, Raymond J. Cadeddu, Jeffrey A. Raman, Jay D. |
author_sort | Loloi, Justin |
collection | PubMed |
description | Management of residual or recurrent disease following thermal ablation of renal cortical tumors includes surveillance, repeat ablation, or surgical extirpation. We present a multicenter experience with regard to the management of this clinical scenario. Prospectively maintained databases were reviewed to identify 1265 patients who underwent cryoablation (CA) or radiofrequency ablation (RFA) for enhancing renal masses. Disease persistence or recurrence was classified into one of the three categories: (i) residual disease in ablation zone; (ii) recurrence in the ipsilateral renal unit; and (iii) metastatic/extra-renal disease. Seventy seven patients (6.1%) had radiographic evidence of disease persistence or recurrence at a median interval of 13.7 months (range, 1–65 months) post-ablation. Distribution of disease included 47 patients with residual disease in ablation zone, 29 with ipsilateral renal unit recurrences (all in ablation zone), and one with metastatic disease. Fourteen patients (18%) elected for surveillance, and the remaining underwent salvage ablation (n = 50), partial nephrectomy (n = 5), or radical nephrectomy (n = 8). Salvage ablation was successful in 38/50 (76%) patients, with 12 failures managed by observation (3), tertiary ablation (6), and radical nephrectomy (3). At a median follow-up of 28 months, the actuarial cancer-specific survival and overall survival in this select cohort of patients was 94.8 and 89.6%, respectively. |
format | Online Article Text |
id | pubmed-7331942 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Codon Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-73319422020-07-13 Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors Loloi, Justin Shingleton, W. Bruce Nakada, Stephen Y. Zagoria, Ronald J. Landman, Jaime Lee, Benjamin R. Matin, Surena F. Ahrar, Kamran Leveillee, Raymond J. Cadeddu, Jeffrey A. Raman, Jay D. J Kidney Cancer VHL Short Communication Management of residual or recurrent disease following thermal ablation of renal cortical tumors includes surveillance, repeat ablation, or surgical extirpation. We present a multicenter experience with regard to the management of this clinical scenario. Prospectively maintained databases were reviewed to identify 1265 patients who underwent cryoablation (CA) or radiofrequency ablation (RFA) for enhancing renal masses. Disease persistence or recurrence was classified into one of the three categories: (i) residual disease in ablation zone; (ii) recurrence in the ipsilateral renal unit; and (iii) metastatic/extra-renal disease. Seventy seven patients (6.1%) had radiographic evidence of disease persistence or recurrence at a median interval of 13.7 months (range, 1–65 months) post-ablation. Distribution of disease included 47 patients with residual disease in ablation zone, 29 with ipsilateral renal unit recurrences (all in ablation zone), and one with metastatic disease. Fourteen patients (18%) elected for surveillance, and the remaining underwent salvage ablation (n = 50), partial nephrectomy (n = 5), or radical nephrectomy (n = 8). Salvage ablation was successful in 38/50 (76%) patients, with 12 failures managed by observation (3), tertiary ablation (6), and radical nephrectomy (3). At a median follow-up of 28 months, the actuarial cancer-specific survival and overall survival in this select cohort of patients was 94.8 and 89.6%, respectively. Codon Publications 2020-06-09 /pmc/articles/PMC7331942/ /pubmed/32665886 http://dx.doi.org/10.15586/jkcvhl.2020.133 Text en Copyright: Loloi J et al. http://creativecommons.org/licenses/by/4.0/ This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Short Communication Loloi, Justin Shingleton, W. Bruce Nakada, Stephen Y. Zagoria, Ronald J. Landman, Jaime Lee, Benjamin R. Matin, Surena F. Ahrar, Kamran Leveillee, Raymond J. Cadeddu, Jeffrey A. Raman, Jay D. Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors |
title | Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors |
title_full | Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors |
title_fullStr | Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors |
title_full_unstemmed | Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors |
title_short | Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors |
title_sort | management of residual or recurrent disease following thermal ablation of renal cortical tumors |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331942/ https://www.ncbi.nlm.nih.gov/pubmed/32665886 http://dx.doi.org/10.15586/jkcvhl.2020.133 |
work_keys_str_mv | AT loloijustin managementofresidualorrecurrentdiseasefollowingthermalablationofrenalcorticaltumors AT shingletonwbruce managementofresidualorrecurrentdiseasefollowingthermalablationofrenalcorticaltumors AT nakadastepheny managementofresidualorrecurrentdiseasefollowingthermalablationofrenalcorticaltumors AT zagoriaronaldj managementofresidualorrecurrentdiseasefollowingthermalablationofrenalcorticaltumors AT landmanjaime managementofresidualorrecurrentdiseasefollowingthermalablationofrenalcorticaltumors AT leebenjaminr managementofresidualorrecurrentdiseasefollowingthermalablationofrenalcorticaltumors AT matinsurenaf managementofresidualorrecurrentdiseasefollowingthermalablationofrenalcorticaltumors AT ahrarkamran managementofresidualorrecurrentdiseasefollowingthermalablationofrenalcorticaltumors AT leveilleeraymondj managementofresidualorrecurrentdiseasefollowingthermalablationofrenalcorticaltumors AT cadeddujeffreya managementofresidualorrecurrentdiseasefollowingthermalablationofrenalcorticaltumors AT ramanjayd managementofresidualorrecurrentdiseasefollowingthermalablationofrenalcorticaltumors |